Ionis Pharmaceuticals Inc (IONS.O)
18 Apr 2019
March 1 An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.
ZURICH Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.
* Novartis aims to build up heart drug portfolio (Adds comment from Novartis drug developer, details of payment and deal)
BRIEF-Ionis Pharmaceuticals - Announced Partner Roche, also known as Genentech In U.S., enrolled first patient in study of Rg6042 for Huntington's disease
* IONIS PHARMACEUTICALS - ANNOUNCED PARTNER ROCHE, ALSO KNOWN AS GENENTECH IN U.S., ENROLLED FIRST PATIENT IN STUDY OF RG6042 FOR HUNTINGTON'S DISEASE